AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $173.7 which represents a slight increase of $2.35 or 1.37% from the prior close of $171.35. The stock opened at $171.45 and touched a ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Tech stocks and growth stocks don't usually correspond with passive income. Companies that are growing their earnings can ...

Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...